Read More
Source link
ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset
Article content VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in…







